药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Racotumomab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Racotumomab.
Difenoxin
Namilumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Namilumab.
Difenoxin
Rovalpituzumab Tesirine
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Rovalpituzumab Tesirine.
Difenoxin
Robatumumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Robatumumab.
Difenoxin
Milatuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Milatuzumab.
Difenoxin
Bimekizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bimekizumab.
Difenoxin
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sacituzumab govitecan.
Difenoxin
Ozanezumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ozanezumab.
Difenoxin
Clazakizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Clazakizumab.
Difenoxin
Amatuximab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Amatuximab.
Difenoxin
Rontalizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Rontalizumab.
Difenoxin
Depatuxizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Depatuxizumab.
Difenoxin
Concizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Concizumab.
Difenoxin
Crotedumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Crotedumab.
Difenoxin
Naptumomab Estafenatox
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Naptumomab Estafenatox.
Difenoxin
Ecromeximab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ecromeximab.
Difenoxin
Abituzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Abituzumab.
Difenoxin
Sifalimumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sifalimumab.
Difenoxin
Demcizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Demcizumab.
Difenoxin
Carlumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Carlumab.